Research from Icahn School of Medicine at Mount Sinai shows it is possible to track how well beneficial microbial strains are taken up by fecal microbiota transplant (FMT) recipients using a combination of long read sequencing and specialized genomic assembly software.

FMT for treatment of recurrent Clostridium difficile infection is now an approved therapy option with two companies achieving FDA approval for their FMT-based treatments in 2022 and 2023.

Although success rates with FMT in C. difficile patients are very high at 85% or higher after only one infusion, gut microbiome-based therapeutics to treat other conditions like inflammatory bowel disease or cancer are still at an early stage of development. This is partly due to the complexity of the gut microbiome, which makes deter

See Full Page